Skip to main content
SpringerLink
Log in

Crizotinib-induced toxicity in an experimental rat model

  • original article
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Summary

Aim

The aim of the present study was to evaluate the effect of crizotinib on visceral organs in an experimental rat model.

Methods

Eighteen Wistar albino rats were divided into three groups: experimental toxicity was induced with crizotinib (10 mg/kg) administered for 28 days (Group 1), 42 days (Group 2) orally by gavage. Control group received only distilled water. Rats in Group 1 and Group 2 were sacrificed after the collection of blood and tissue samples on the 28th and 42nd days, respectively.

Results

Subjects in Group 1 and Group 2 had abnormal histology mainly in lung and liver. There were intraalveolar hemorrhage in lungs; mild portal inflammation, perivenular focal and confluent necrosis in liver; inflammatory reaction in renal pelvis and periureteral areas, and focal pancreatitis in pancreas.

Conclusion

This study is the first to evaluate the histopathological features of toxicity of crizotinib in a rat model.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  2. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.

    Article  PubMed  Google Scholar 

  3. Collins LG, Haines C, Perkel R, et al. Lung cancer: diagnosis and management. Am Fam Physician. 2007;75(1):56–63.

    PubMed  Google Scholar 

  4. Alberts WM. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest. 2007;132(3 Suppl):1S–19S.

    Article  PubMed  Google Scholar 

  5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.

    Article  CAS  PubMed  Google Scholar 

  6. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.

    Article  CAS  PubMed  Google Scholar 

  7. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6.

    Article  CAS  PubMed  Google Scholar 

  9. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6(5):942–6.

    Article  PubMed  Google Scholar 

  10. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–94.

    Article  CAS  PubMed  Google Scholar 

  12. Stahel RA, Rosell R, Thatcher N, Soria JC. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer. 2012;48(7):961–73.

    Article  PubMed  Google Scholar 

  13. Crinò L, Kim D, Riely GJ, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol. 2011;29 (suppl; abstr 7514).

  14. Smith EB, Goulet L, Walker GS, et al. Metabolism and excretion of Crizotinib in rats and dogs. 17th North American Regional International society for the study of xenobiotics Meeting. (P82).

  15. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Qian H, Gao F, Wang H, et al. The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials. BMC Cancer. 2014;14:683.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Loriot Y, Perlemuter G, Malka D, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol. 2008;5(5):268–78.

    Article  CAS  PubMed  Google Scholar 

  18. Demirci U, Buyukberber S, Yılmaz G, et al. Hepatotoxicity associated with lapatinib in an experimental rat model. Eur J Cancer. 2012;48(2):279–85.

    Article  CAS  PubMed  Google Scholar 

  19. Ripault MP, Pinzani V, Fayolle V, et al. Crizotinib-induced acute hepatitis: first case with relapse after reintroduction with reduced dose. Clin Res Hepatol Gastroenterol. 2013;37(1):e21–3.

    Article  PubMed  Google Scholar 

  20. Sato Y, Fujimoto D, Shibata Y, et al. Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma. Jpn J Clin Oncol. 2014;44(9):872–5.

    Article  PubMed  Google Scholar 

  21. Pariente A, Etcharry F, Cales V, et al. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Eur J Gastroenterol Hepatol. 2006;18(7):785–7.

    Article  PubMed  Google Scholar 

  22. Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99(7):2310–4.

    Article  PubMed  Google Scholar 

  23. Ono A, Takahashi T, Oishi T, et al. Acute lung injury with alveolar hemorrhage as adverse drug reaction related to crizotinib. J Clin Oncol. 2013;31(26):e417–9.

    Article  PubMed  Google Scholar 

  24. Muller NL, White DA, Jiang H, et al. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer. 2004;91:S24–S30.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006;24:2549–56.

    Article  CAS  PubMed  Google Scholar 

  26. Higenbottam T, Kuwano K, Nemery B, et al. Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer. 2004;91(Suppl 2):S31–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361(9352):137–9.

    Article  PubMed  Google Scholar 

  28. Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120(2):617–24.

    Article  CAS  PubMed  Google Scholar 

  29. Tirumani SH, Jagannathan JP, Shinagare AB, et al. Acute pancreatitis associated with molecular targeted therapies: a retrospective review of the clinico-radiological features, management and outcome. Pancreatology. 2013;13(5):461–7.

    Article  CAS  PubMed  Google Scholar 

  30. Rothenstein JM, Letarte N. Managing treatment-related adverse events associated with Alk inhibitors. Curr Oncol. 2014;21(1):19–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Martín Martorell P, Huerta Alvaro M, Solís Salguero MA, et al. Crizotinib and renal insufficiency: a case report and review of the literature. Lung Cancer. 2014;84(3):310–3.

    Article  PubMed  Google Scholar 

  32. Brosnan EM, Weickhardt AJ, Lu X, et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer. 2014;120(5):664–74.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

O. Gumusay, G. Esendagli-Yilmaz, A. Uner, B. Cetin, S. Buyukberber, M. Benekli, M. N. Ilhan, U. Coskun, O. Gulbahar, and A. Ozet declare that there are no actual or potential conflicts of interest in relation to this article. The authors received no additional financial support or national funding for this study. There is no substantial contribution provided by a person different from the authors. This submission has not been published anywhere previously and that it is not simultaneously being considered for any other publication.

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Gaziosmanpasa University, 60250, Tokat, Turkey

    Ozge Gumusay MD

  2. Department of Medical Pathology, Faculty of Medicine, Gazi University, Ankara, Turkey

    Guldal Esendagli-Yilmaz

  3. Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey

    Aytug Uner, Suleyman Buyukberber, Mustafa Benekli, Ugur Coskun & Ahmet Ozet

  4. Department of Internal Medicine, Division of Medical Oncology, Cumhuriyet University Sivas, Sivas, Turkey

    Bulent Cetin

  5. Department of Public Health, Faculty of Medicine, Gazi University, Ankara, Turkey

    Mustafa N. Ilhan

  6. Department of Biochemistry, Faculty of Medicine, Gazi University, Ankara, Turkey

    Ozlem Gulbahar

Authors
  1. Ozge Gumusay MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guldal Esendagli-Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aytug Uner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bulent Cetin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Suleyman Buyukberber
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mustafa Benekli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mustafa N. Ilhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ugur Coskun
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ozlem Gulbahar
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ahmet Ozet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ozge Gumusay MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gumusay, O., Esendagli-Yilmaz, G., Uner, A. et al. Crizotinib-induced toxicity in an experimental rat model. Wien Klin Wochenschr 128, 435–441 (2016). https://doi.org/10.1007/s00508-016-0984-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-016-0984-y

Keywords

Search

Navigation